MELBOURNE, Australia and MENLO PARK, Calif., March 5 /PRNewswire/ -- ChemGenex Pharmaceuticals Limited announced today that Greg Collier PhD, Chief Executive Officer and managing director, will present a company update at the Cowen & Co. 26th Annual Health Care Conference on Monday, March 6th, at 2:20 pm ET in the Province Town Meeting Room on the 3rd floor at the Boston Marriott Copley Place.
Dr. Collier's presentation will provide an overview of ChemGenex's development pipeline, focusing on recent advances in the company's clinical programs, Ceflatonin(R) (HHT), in phase 2/3 for the treatment of leukemias and Quinamed(R) (amonafide dihydrochloride), in phase 2 for the treatment of solid tumors.
A live audio webcast of the presentation will be available from the company's website, http://www.chemgenex.com. An audio replay of the presentation will be available for 90 days after the conference.
About ChemGenex Pharmaceuticals Limited (http://www.chemgenex.com)
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex's lead compound, Ceflatonin(R), is currently in phase 2/3 clinical trials for leukemia and Quinamed(R) is in phase 2 clinical trials for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".
Safe Harbor Statement
Certain statements made herein that use the words "estimate," 'project," "intend," "expect," "believe," and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development , the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
ChemGenex Pharmaceuticals Limited
CONTACT: Dr. Greg Collier, CEO and Managing Director, Australia,+61-3-5227-2752, USA, +1-650-474-9800 ext. 103, or Dr. Dennis Brown,President and Director, USA, +1-650-474-9800 ext. 108, Australia ,+61-3-5227-2703, both of ChemGenex Pharmaceuticals Limited